Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solana Company (NASDAQ: HSDT) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures, including Forms 10-K, 10-Q, 8-K, proxy statements, and other required reports. These documents offer detailed insight into Solana Company’s dual focus as a neurotech medical device issuer and a Solana-centric digital asset treasury.
In its filings, Solana Company describes its operations in the electromedical and electrotherapeutic apparatus manufacturing industry and outlines its orally applied technology platform for neurologic deficits. Quarterly and annual reports, such as the Form 10-K and Form 10-Q, present financial statements, revenue components (including staking rewards and other revenue), operating expenses, research and development costs, and unrealized gains or losses on digital assets.
Current reports on Form 8-K document material events, including the name change from Helius Medical Technologies, Inc. to Solana Company, the adoption of a Solana-focused digital asset treasury, PIPE financings, warrant issuances, stock repurchase authorizations, changes in independent registered public accounting firms, and board and governance developments. Proxy materials on Schedule 14A describe matters submitted to stockholders, such as director elections, equity incentive plan amendments, and approvals related to cryptocurrency-linked warrants.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex items such as derivative liabilities tied to stapled warrants, digital asset treasury activities, or auditor changes. Users can review real-time updates from EDGAR, track quarterly (10-Q) and annual (10-K) reports, and examine Form 4 and related disclosures of insider transactions where available, all supported by concise AI explanations that clarify terminology and context.
Solana Company reported a change in its independent auditor. On October 15, 2025, Baker Tilly US, LLP resigned as the Company’s independent registered public accounting firm, and the Audit Committee approved the appointment of CBIZ CPAs P.C. as auditor for the fiscal year ending December 31, 2025.
Baker Tilly’s audit reports for 2024 and 2023 had an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. The Company states there were no disagreements and no reportable events with Baker Tilly through October 15, 2025. A confirming letter from Baker Tilly is filed as Exhibit 16.1.
Solana Company (f/k/a Helius Medical Technologies) called a virtual special meeting to vote on five proposals. The agenda includes electing one new director, authorizing share issuances upon exercise of specific warrants under Nasdaq Listing Rule 5635(a), amending the 2022 Equity Incentive Plan to add 4,000,000 shares, and permitting adjournments if needed.
Proposal 2 seeks approval for issuances upon exercise of Strategic Advisor Warrants held by Pantera Capital Management LP and Summer Wisdom Holdings Limited. Proposal 3 seeks approval for issuances upon exercise of Cryptocurrency Pre-Funded and Cryptocurrency Stapled Warrants issued for consideration in Solana (SOL) cryptocurrency. The Board unanimously recommends voting FOR the director nominee and FOR Proposals 2, 3, 4 and 5.
The meeting is fully virtual, and only stockholders of record as of September 26, 2025 may vote. Shares outstanding were 40,299,220 as of September 26, 2025. The company also disclosed one-time discretionary cash bonuses of $890,000 (CEO) and $610,000 (CFO) under side letters, which will offset any severance or similar cash amounts.
Helius Medical Technologies, Inc. is soliciting proxies for a virtual special meeting to consider five proposals including the election of one director, Nasdaq approvals for issuance of shares on exercise of warrants tied to strategic advisors Pantera Capital and Summer Wisdom and warrants tied to acceptance of Solana (SOL) cryptocurrency, and an amendment to increase available shares under the 2022 Equity Incentive Plan by 4,000,000 shares. The Board unanimously recommends voting FOR the director nominee and Proposals 2–4. The record date is September 26, 2025 and there were 40,299,220 shares outstanding on that date. The filing discloses executive compensation policies, 2024 base salaries and bonus outcomes (Bonuses paid at 83% of target), significant equity grants in 2024 (e.g., options of 808,000 shares to the CEO), and September 24, 2025 side letters providing one-time cash bonuses of $890,000 and $610,000 to the CEO and CFO respectively, offsetting other potential post-transaction payments. The document details committee structure, independence determinations, and insider trading and clawback policies.
Solana Rocket Holdings Limited and CHUNG Wai Shing jointly disclosed beneficial ownership in Helius Medical Technologies (HSDT). They report shared voting and dispositive power over 4,040,871 Class A shares, representing 9.99% of the outstanding shares based on 40,295,612 shares outstanding as of September 24, 2025. Solana Rocket directly holds 3,887,319 shares plus pre-funded warrants for up to 10,936,107 shares and cash stapled warrants for up to 14,823,426 shares. A Beneficial Ownership Blocker limits exercise of the warrants so the reporting persons are capped at 9.99% (calculated to include 153,552 shares issuable under partial exercise). The filing includes a joint filing agreement as Exhibit 99.1.
Fusion Summer Limited and CHEE Choon Wee disclosed a joint Schedule 13D reporting the acquisition of 6,830,402 shares of Helius Medical Technologies Class A common stock, representing 17.0% of the outstanding shares based on 40,295,612 shares. Fusion Summer paid approximately $47.0 million in a private placement (PIPE) that closed on September 18, 2025. Mr. CHEE, the ultimate controller of Fusion Summer, was appointed Executive Chairman effective at closing. The reporting persons hold shared voting and dispositive power over the shares and state the securities were acquired for investment purposes.
Helius Medical Technologies, Inc. filed an Form 8-K reporting corporate governance document updates effective September 29, 2025. The filing lists a Certificate of Amendment to the Certificate of Incorporation filed with Delaware on September 26, 2025 and effective September 29, 2025, a Third Amended and Restated Bylaws effective September 29, 2025, and a press release issued on September 29, 2025. The filing is signed by Jeffrey S. Mathiesen and includes an Inline XBRL cover page file.
Chee Choon Wee filed a Form 3 reporting initial beneficial ownership in Helius Medical Technologies, Inc. (HSDT). The filing shows 6,830,402 shares of common stock held indirectly through Fusion Summer Limited, 6,830,402 stapled warrants exercisable from 09/18/2025 for 36 months at a $10.134 exercise price, and 1,109,118 restricted stock units granted 09/18/2025, each convertible into one share under the companys 2022 Equity Incentive Plan.
Helius Medical Technologies reported new executive compensation arrangements and a key regulatory step for its neuromodulation device. The company entered into side letter agreements with President and CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen, granting one-time discretionary cash bonuses of $890,000 and $610,000, respectively. These cash bonuses will be offset dollar-for-dollar against any future severance, bonus, equity, retirement or other benefits the executives might otherwise receive under company plans or their employment agreements.
In return, both executives agreed that offerings completed on September 18, 2025 do not count as a change in control or trigger a good reason event under their employment agreements. Separately, Helius announced it has filed a U.S. FDA 510(k) submission seeking to expand the label for its Portable Neuromodulation Stimulator device to include gait and balance deficit in patients with chronic stroke symptoms, using data from its Stroke Registrational Program under its existing Breakthrough Device Designation.
Helius Medical Technologies, Inc. filed a current report to furnish information under Regulation FD. The company stated that on September 22, 2025 it issued a press release and attached this release as Exhibit 99.1 to the report. The filing does not describe the contents of the press release, instead directing readers to the attached exhibit for details.
Helius Medical Technologies completed a $500 million PIPE on September 18, 2025 and launched a Solana-centric digital asset treasury strategy to acquire SOL via open-market purchases and build Solana treasury operations. The PIPE included cash and cryptocurrency purchasers buying combinations of common shares, pre-funded warrants and stapled warrants; exercise of the cryptocurrency-related warrants is conditioned on stockholder approval. The company’s PoNS® portable neuromodulation device is cleared in the U.S. for short-term treatment of gait deficit due to mild-to-moderate MS, authorized in Canada for three indications and is Class IIa in Australia. Common stock trades on Nasdaq under HSDT (last reported price $23.17 on September 18, 2025) and there were 39,382,328 shares outstanding as of September 18, 2025.